This live web event has ended. Thank you for attending. 0 of 9 Sessions Available SEP 12 September 12, 2019 Thu 7:00 PM EDT 1H Closed Emily Stamell Ruiz, MD, MPH NOV 13 November 13, 2019 Wed 12:00 PM EST 1H Closed Ann Silk, MD, MS JUN 24 June 24, 2020 Wed 6:00 PM EDT 1H Closed Emily Stamell Ruiz, MD, MPH SEP 23 September 23, 2020 Wed 12:30 PM EDT 1H Closed SEP 29 September 29, 2020 Tue 9:00 AM EDT 1H Closed OCT 29 October 29, 2020 Thu 11:45 AM EDT 1H Closed DEC 10 December 10, 2020 Thu 12:15 PM CST 1H Closed JAN 20 January 20, 2021 Wed 8:00 AM EST 1H Closed MAR 05 March 05, 2021 Fri 12:15 PM EST 1H Closed Contributors Emily Stamell Ruiz, MD, MPH Director, Dana‐Farber/Brigham and Women's High‐Risk Skin Cancer Clinic Associate Physician Dana‐Farber/Brigham and Women's Cancer Center Instructor in Dermatology Harvard Medical School Boston, MA Emily Stamell Ruiz, MD, MPH is Director of the Dana-Farber/Brigham and Women’s High-Risk Skin Cancer Clinic, an Associate Physician at the Mohs and Dermatologic Surgery Center at Dana-Farber/Brigham and Women’s Cancer Center, and an Instructor in Dermatology at Harvard Medical School. Dr. Ruiz received her undergraduate degree from Duke University, her medical degree from New York University School of Medicine, and her Master of Public Health degree from Harvard School of Public Health.Dr. Ruiz completed an internship in internal medicine at New York University School of Medicine, a dermatology residency at Albert Einstein College of Medicine, and a fellowship in micrographic surgery and dermatologic oncology at Brigham and Women’s Hospital. Dr. Ruiz’s research focuses on the burden of skin cancer through health services research and nonmelanoma skin cancer outcomes studies. Ann Silk, MD, MS Medical Oncologist Dana-Farber Cancer Institute Boston, MA Ann W. Silk, MD, MS is a medical oncologist at Dana‐Farber Cancer Institute, where she specializes in the care of patients with advanced skin cancers, including squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, and melanoma. She conducts clinical trials using immuno-therapeutics, such as immune checkpoint inhibitors, cytokine therapy, and oncolytic viral therapy.Dr. Silk received her medical doctorate and master’s degree in clinical research at the University of Pittsburgh in 2008. She completed a clinical fellowship in hematology and oncology at the University of Michigan in 2014. She joined the faculty at Dana-Farber Cancer Institute in 2019.